• James J Chamberlain, William H Herman, Sandra Leal, Andrew S Rhinehart, Jay H Shubrook, Neil Skolnik, and Rita Rastogi Kalyani.
• From St. Mark's Hospital and St. Mark's Diabetes Center, Salt Lake City, Utah; University of Michigan, Ann Arbor, Michigan; SinfoníaRx, Tucson, Arizona Glytec, Greenville, South Carolina; Touro University College of Osteopathic Medicine, Vallejo, California; Abington-Jefferson Health, Jenkintown, Pennsylvania; and Johns Hopkins University, Baltimore, Maryland.
• Ann. Intern. Med. 2017 Apr 18; 166 (8): 572-578.

DescriptionThe American Diabetes Association (ADA) annually updates the Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes.MethodsFor the 2017 Standards, the ADA Professional Practice Committee updated previous MEDLINE searches performed from 1 January 2016 to November 2016 to add, clarify, or revise recommendations based on new evidence. The committee rates the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions.RecommendationsThis synopsis focuses on recommendations from the 2017 Standards about pharmacologic approaches to glycemic treatment of type 2 diabetes.

22 keywords...

hide…